DOCSLIB.ORG

Table S3: List of EGFR Pathway-Regulated Genes. Gene Name Fold Fold

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Table S3: List of EGFR pathway-regulated genes. Gene Name Fold Fold EGF4h/Control EGF12h/Control Up-regulated by EGFR activation Increased at 4 hours but declined at 12 hours A kinase (PRKA) anchor protein (gravin) 12 7.67 1.58 Ab2-427 3.05 0.99 acyl-CoA synthetase long-chain family member 1 3.88 0.94 acyl-CoA synthetase long-chain family member 4 6.25 3.58 adipose differentiation-related protein 5.46 3.51 Aldehyde dehydrogenase family 1, subfamily A3 38.45 1.78 amphiregulin 77.79 27.77 arginase 1 4.10 2.06 arginosuccinate synthetase 3.00 1.19 aryl hydrocarbon receptor 5.03 1.55 ATPase, Ca++ transporting, plasma membrane 1 4.08 2.31 basic helix-loop-helix domain containing, class B2 7.86 4.12 Basophilic leukemia expressed sequence 06 (Bles06) 2.89 1.17 BH3 interacting domain death agonist 3.09 1.17 brain-specific angiogenesis inhibitor 1-associated protein 2 7.73 2.80 breast cancer anti-estrogen resistance 3 (predicted) 3.71 1.85 bridging integrator 1 6.07 2.08 cellular retinoic acid binding protein 2 2.47 1.11 charged amino acid rich leucine zipper 1 (predicted) 2.22 1.25 chemokine (C-C motif) ligand 2 3.29 1.34 chemokine (C-C motif) ligand 20 5.91 0.98 Chemotactic protein-3 3.82 -2.1 cryptochrome 1 (photolyase-like) 2.99 0.51 cyclin H 2.26 1.34 cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 3.25 1.25 cysteine knot superfamily 1, BMP antagonist 1 20.20 3.28 cytokine receptor-like factor 1 (predicted) 5.43 1.23 death-associated kinase 2 (predicted) 5.03 3.07 DEAD (Asp-Glu-Ala-Asp) box polypeptide 27 (predicted) 2.46 1.38 decay accelarating factor 1 5.85 2.82 dehydrogenase/reductase (SDR family) member 9 3.22 1.13 diphtheria toxin receptor 9.99 5.16 dual specificity phosphatase 5 29.54 12.07 early growth response 2 7.99 2.54 endothelial differentiation sphingolipid G-protein-coupled receptor 1 6.05 1.05 endothelial differentiation, sphingolipid G-protein-coupled receptor, 5 3.03 1.36 endothelin receptor type A 2.59 0.57 eukaryotic translation initiation factor 4E 2.41 1.29 FK506 binding protein 5 (predicted) 10.11 3.03 FMS-like tyrosine kinase 1 3.74 1.51 follistatin 10.82 6.51 forkhead box P1 (predicted) 2.83 1.27 fos-like antigen 1 41.47 8.70 glutamate-rich WD repeat containing 1 (predicted) 2.59 1.07 glutaredoxin 1 (thioltransferase) 4.13 2.08 Guanosine monophosphate reductase 2 3.09 1.12 heat shock protein 2 2.85 0.50 hexokinase 2 20.80 1.69 high mobility group AT-hook 1 6.40 4.28 homer homolog 1 (Drosophila) 2.35 1.36 hormone-regulated proliferation-associated 20 kDa protein 3.00 1.20 hyaluronan synthase 2 8.46 3.38 IBR domain containing 3 (predicted) 2.57 1.15 keratinocytes proline-rich protein 5.03 3.20 kinesin family member C3 (predicted) 4.60 2.35 leucine-rich repeat-containing 5 (predicted) 2.69 1.05 leukemia inhibitory factor 2.33 1.30 linker of T-cell receptor pathways 6.74 2.70 Ly1 antibody reactive clone (predicted) 3.47 1.92 lysosomal trafficking regulator 5.22 1.41 met proto-oncogene 3.61 1.64 methionine adenosyltransferase II, alpha 2.41 1.07 M-phase phosphoprotein 10 (U3 small nucleolar ribonucleoprotein) 2.86 1.11 myelocytomatosis viral oncogene homolog (avian) 4.56 2.69 myeloid cell nuclear differentiation antigen (predicted) 27.09 12.32 myosin IE 5.16 2.54 myosin IG (predicted) 4.94 3.25 myeloid differentiation primary response gene 116 2.68 1.31 nerve growth factor, beta 7.88 1.66 Notch gene homolog 1, (Drosophila) 3.41 1.21 Notch-regulated ankyrin repeat protein (predicted) 4.47 1.17 nucleolar and coiled-body phosphoprotein 1 2.62 1.34 Nucleoporin like 1 3.98 1.96 oxidized low density lipoprotein (lectin-like) receptor 1 10.30 1.52 peptidylprolyl isomerase F (cyclophilin F) 2.66 0.94 Phosphoribosyl pyrophosphate amidotransferase 3.45 1.39 plasminogen activator, urokinase receptor 21.00 7.15 pleckstrin homology, Sec7 and coiled-coil domains 3 8.18 1.91 pleckstrin homology-like domain, family A, member 1 5.90 1.63 prostaglandin-endoperoxide synthase 2 26.84 6.09 protein kinase C, alpha 4.65 2.85 protein phosphatase 2C, magnesium-dependent, catalytic subunit 7.25 2.59 putative phosphate-phosphoenolpyruvate translocator 4.05 1.76 putative scaffolding protein POSH 3.36 1.69 putative small membrane protein NID67 8.11 3.12 RAB20, member RAS oncogene family (predicted) 3.62 1.60 receptor (calcitonin) activity modifying protein 3 5.76 2.48 receptor (TNFRSF)-interacting serine-threonine kinase 2 (predicted) 6.34 2.28 receptor-interacting serine-threonine kinase 3 13.27 8.69 regulator of G-protein signaling 2 33.68 1.69 RNA polymerase 1-2 3.31 1.10 saccharomyces cerevisiae Nip7p homolog 3.03 1.51 semaphorin 4B (predicted) 8.12 2.35 Ser/Thr-like protein kinase lyk4 4.02 1.55 serine (or cysteine) proteinase inhibitor, clade B, member 2 437.35 35.98 serine (or cysteine) proteinase inhibitor, clade E, member 2 11.05 5.67 serum/glucocorticoid regulated kinase 23.80 2.82 sialyltransferase 1 5.55 0.99 stanniocalcin 1 3.24 1.18 Tenascin C 5.83 0.73 TERF1 (TRF1)-interacting nuclear factor 2 6.72 1.14 TGFB inducible early growth response 3.33 1.53 transducin-like enhancer of split 3, E(spl) homolog (Drosophila) 2.69 0.65 Transferrin receptor 5.25 2.18 Transforming growth factor, beta receptor 1 2.69 1.19 transglutaminase 1 9.04 1.01 transmembrane 4 superfamily member 9 6.04 2.15 tribbles homolog 1 (Drosophila) 4.64 1.97 trinucleotide repeat containing 15 (predicted) 4.19 1.28 tumor necrosis factor, alpha-induced protein 2 (predicted) 6.41 2.40 twist gene homolog 1 (Drosophila) 3.42 1.49 twist homolog 2 (Drosophila) 5.49 1.80 UDP-N-acetylglucosamine pyrophosphorylase 1 (predicted) 16.12 6.80 v-jun sarcoma virus 17 oncogene homolog (avian) 5.42 3.21 WD repeat domain 3 (predicted) 2.32 1.04 zinc finger protein 36, C3H type-like 2 (predicted) 3.42 1.00 zinc finger, DHHC domain containing 13 (predicted) 2.72 1.11 Increased continuously over 12 hours 20 alpha-hydroxysteroid dehydrogenase 8.53 55.51 aldo-keto reductase family 1, member B8 18.62 36.27 branched chain aminotransferase 1, cytosolic 2.92 9.21 chondroitin sulfate proteoglycan 2 3.12 17.75 ectonucleotide pyrophosphatase/phosphodiesterase 1 5.08 8.12 EH-domain containing 4 3.48 5.20 endothelial cell-specific molecule 1 3.20 17.08 epithelial membrane protein 3 2.52 4.55 glucosaminyl (N-acetyl) transferase 1, core 2 15.45 17.87 Integrin, alpha 6 3.14 5.08 interleukin 1 receptor-like 1 14.49 29.46 isopentenyl-diphosphate delta isomerase 3.43 5.31 latent transforming growth factor beta binding protein 1 2.50 5.05 lectin, galactose binding, soluble 3 3.22 9.28 matrix metallopeptidase 24 4.46 16.41 microtubule-associated protein 1b 3.71 5.31 neuron navigator 1 (predicted) 3.49 6.35 nidogen 2 (predicted) 2.56 5.99 Phosphofructokinase, platelet 2.29 3.76 Plasminogen activator, urokinase 2.18 6.00 progressive ankylosis homolog (mouse) 13.45 17.35 protein C receptor, endothelial (predicted) 4.13 19.13 Rho GTPase activating protein 22 (predicted) 4.04 20.08 serine (or cysteine) proteinase inhibitor, clade E, member 1 2.80 4.49 solute carrier family 7 (cationic amino acid transporter, y+ system), 12.84 15.73 -member 8 squalene epoxidase 4.68 7.53 Increased to a plateau after 4 hours acetoacetyl-CoA synthetase 2.42 2.63 Adiponectin receptor 2 3.17 2.84 ATPase family, AAA domain containing 3A (predicted) 2.81 1.47 AXL receptor tyrosine kinase (predicted) 2.38 3.13 Basic helix-loop-helix domain containing, class B2 3.34 3.07 basic leucine zipper and W2 domains 2 2.64 3.70 B-cell CLL/lymphoma 10 2.84 2.15 block of proliferation 1 (predicted) 2.68 1.54 bradykinin receptor b2 4.32 4.03 brain protein 16 2.62 1.37 branched chain aminotransferase 1, cytosolic 5.05 3.65 brix domain containing 1 (predicted) 2.66 1.75 caspase 8 2.43 1.49 CD44 antigen 7.70 8.01 coagulation factor II (thrombin) receptor-like 1 2.67 1.58 Core promoter element binding protein 2.58 3.83 cytoplasmic linker 2 3.32 1.90 dual specificity phosphatase 14 (predicted) 2.34 1.55 dual specificity phosphatase 6 5.55 6.62 epidermal growth factor receptor pathway substrate 8 (predicted) 2.96 2.71 epithelial membrane protein 1 2.52 3.00 eukaryotic translation initiation factor 2B, subunit 3 gamma 2.89 2.10 fibroblast growth factor 2 5.32 3.95 GERp95 3.16 2.32 growth arrest specific 7 3.52 2.83 huntingtin interacting protein 1 2.97 1.86 hydroxysteroid (17-beta) dehydrogenase 7 4.65 5.81 Hypoxia induced gene 1 2.74 2.24 influenza virus NS1A binding protein (predicted) 2.84 1.59 interferon-related developmental regulator 1 3.74 3.87 karyopherin (importin) beta 3 (predicted) 4.20 3.54 lamin A 2.81 2.28 mesoderm development candidate 1 (predicted) 3.54 2.08 microtubule-associated protein 6 3.13 3.45 mitogen activated protein kinase kinase 3 (predicted) 2.67 1.27 mitogen-activated protein kinase 6 2.37 3.10 mitogen-activated protein kinase kinase kinase kinase 4 (predicted) 2.21 1.61 monocyte to macrophage differentiation-associated 5.11 5.70 myeloid cell leukemia sequence 1 2.67 2.49 natriuretic peptide precursor type B 5.31 5.21 nestin 5.51 4.99 neural visinin-like Ca2+-binding protein type 3 2.50 2.23 nuclear RNA helicase, DECD variant of DEAD box family 2.61 3.55 nucleolar protein 1 (predicted) 3.15 1.73 nucleolar protein 5 2.26 1.85 nucleolar protein 5A (predicted) 2.36 1.70 opioid growth factor receptor-like 1 (predicted) 4.81 4.65 ornithine decarboxylase 1 2.74 1.74 ornithine decarboxylase antizyme inhibitor 2.76 1.58 peroxisome proliferative activated receptor, 2.60 1.91 gamma, coactivator-related 1 phosphatidylserine receptor (predicted) 2.51 2.05 phospholipase A2, group IVA (cytosolic, calcium-dependent) 4.43
Recommended publications
  • The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival In

    The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival In

    www.nature.com/scientificreports OPEN The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Received: 20 October 2017 Accepted: 2 February 2018 Promotes Tumor Cell Survival in Published: xx xx xxxx Neurospheres Andrew S. Gilder1, Letizia Natali1, Danielle M. Van Dyk1, Cristina Zalfa1, Michael A. Banki1, Donald P. Pizzo1, Huawei Wang 1, Richard L. Klemke1, Elisabetta Mantuano 1,2 & Steven L. Gonias1 PLAUR encodes the urokinase receptor (uPAR), which promotes cell survival, migration, and resistance to targeted cancer therapeutics in glioblastoma cells in culture and in mouse model systems. Herein, we show that patient survival correlates inversely with PLAUR mRNA expression in gliomas of all grades, in glioblastomas, and in the subset of glioblastomas that demonstrate the mesenchymal gene expression signature. PLAUR clusters with genes that defne the more aggressive mesenchymal subtype in transcriptome profles of glioblastoma tissue and glioblastoma cells in neurospheres, which are enriched for multipotent cells with stem cell-like qualities. When PLAUR was over-expressed or silenced in glioblastoma cells, neurosphere growth and expression of mesenchymal subtype biomarkers correlated with uPAR abundance. uPAR also promoted glioblastoma cell survival in neurospheres. Constitutively-active EGF Receptor (EGFRvIII) promoted neurosphere growth; however, unlike uPAR, EGFRvIII did not induce the mesenchymal gene expression signature. Immunohistochemical analysis of human glioblastomas showed that uPAR is typically expressed by a small sub-population of the cancer cells; it is thus reasonable to conclude that this subpopulation of cells is responsible for the efects of PLAUR on patient survival. We propose that uPAR-expressing glioblastoma cells demonstrate a mesenchymal gene signature, an increased capacity for cell survival, and stem cell-like properties.
  • Cómo Citar El Artículo Número Completo Más Información Del

    Cómo Citar El Artículo Número Completo Más Información Del

    Revista de Biología Tropical ISSN: 0034-7744 ISSN: 0034-7744 Universidad de Costa Rica Alpízar-Alpízar, Warner; Malespín-Bendaña, Wendy; Une, Clas; Ramírez-Mayorga, Vanessa Relevance of the plasminogen activation system in the pathogenesis and progression of gastric cancer Revista de Biología Tropical, vol. 66, núm. 1, 2018, pp. 28-47 Universidad de Costa Rica DOI: 10.15517/rbt.v66i1.29014 Disponible en: http://www.redalyc.org/articulo.oa?id=44955366003 Cómo citar el artículo Número completo Sistema de Información Científica Redalyc Más información del artículo Red de Revistas Científicas de América Latina y el Caribe, España y Portugal Página de la revista en redalyc.org Proyecto académico sin fines de lucro, desarrollado bajo la iniciativa de acceso abierto Relevance of the plasminogen activation system in the pathogenesis and progression of gastric cancer Warner Alpízar-Alpízar1,2*, Wendy Malespín-Bendaña3, Clas Une3 & Vanessa Ramírez-Mayorga3,4 1. Centro de Investigación en Estructuras Microscópicas (CIEMic), Universidad de Costa Rica, San José, Costa Rica; [email protected] 2. Departamento de Bioquímica, Escuela de Medicina, Universidad de Costa Rica, San José, Costa Rica. 3. Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San José, Costa Rica; [email protected], [email protected], [email protected] 4. Sección de Nutrición Pública, Escuela de Nutrición, Universidad de Costa Rica, San José, Costa Rica. * Correspondence Received 14-VII-2017. Corrected 18-X-2017. Accepted 16-XI-2017. Abstract: Gastric cancer is ranked as the third death-causing cancer and one of the most incident malignancies worldwide.
  • Of GTP-Binding Proteins: ARF, ARL, and SAR Proteins

    Of GTP-Binding Proteins: ARF, ARL, and SAR Proteins

    Published Online: 27 February, 2006 | Supp Info: http://doi.org/10.1083/jcb.200512057 JCB: COMMENT Downloaded from jcb.rupress.org on May 9, 2019 <doi>10.1083/jcb.200512057</doi><aid>200512057</aid>Nomenclature for the human Arf family of GTP-binding proteins: ARF, ARL, and SAR proteins Richard A. Kahn,1 Jacqueline Cherfi ls,2 Marek Elias,3 Ruth C. Lovering,4 Sean Munro,5 and Annette Schurmann6 1Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322 2Laboratoire d’Enzymologie et Biochimie Structurales, Centre National de la Recherche Scientifi que, 91198 Gif-sur-Yvette, France 3Department of Plant Physiology, Faculty of Science, Charles University, 128 44 Prague 2, Czech Republic 4Human Genome Organisation Gene Nomenclature Committee, Galton Laboratory, Department of Biology, University College London, London NW1 2HE, United Kingdom 5Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 2QH, United Kingdom 6Department of Pharmacology, German Institute of Human Nutrition Potsdam-Rehbrücke, D-14558 Nuthetal, Germany The Ras superfamily is comprised of at least four large they have been found to be ubiquitous regulators of membrane families of regulatory guanosine triphosphate–binding traffi c and phospholipid metabolism in eukaryotic cells (for re- views and discussion of Arf actions see Nie et al., 2003; Burd proteins, including the Arfs. The Arf family includes three et al., 2004; Kahn, 2004). Arfs are soluble proteins that translocate different groups of proteins: the Arfs, Arf-like (Arls), and onto membranes in concert with their activation, or GTP bind- SARs. Several Arf family members have been very highly ing. The biological actions of Arfs are thought to occur on mem- conserved throughout eukaryotic evolution and have branes and to result from their specifi c interactions with a large orthologues in evolutionally diverse species.
  • Receptor-Like 1 and -Like 2 Is an Endogenous Ligand for Formyl Peptide Through a Urokinase Receptor Epitope That Urokinase Induc

    Receptor-Like 1 and -Like 2 Is an Endogenous Ligand for Formyl Peptide Through a Urokinase Receptor Epitope That Urokinase Induc

    Urokinase Induces Basophil Chemotaxis through a Urokinase Receptor Epitope That Is an Endogenous Ligand for Formyl Peptide Receptor-Like 1 and -Like 2 This information is current as of May 10, 2019. Amato de Paulis, Nunzia Montuori, Nella Prevete, Isabella Fiorentino, Francesca Wanda Rossi, Valeria Visconte, Guido Rossi, Gianni Marone and Pia Ragno J Immunol 2004; 173:5739-5748; ; doi: 10.4049/jimmunol.173.9.5739 http://www.jimmunol.org/content/173/9/5739 Downloaded from References This article cites 65 articles, 33 of which you can access for free at: http://www.jimmunol.org/content/173/9/5739.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on May 10, 2019 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2004 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Urokinase Induces Basophil Chemotaxis through a Urokinase Receptor Epitope That Is an Endogenous Ligand for Formyl Peptide Receptor-Like 1 and -Like 21 Amato de Paulis,* Nunzia Montuori,† Nella Prevete,* Isabella Fiorentino,* Francesca Wanda Rossi,* Valeria Visconte,‡ Guido Rossi,‡ Gianni Marone,2* and Pia Ragno† Basophils circulate in the blood and are able to migrate into tissues at sites of inflammation.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Figure S1. Quality Control Validation of MS Data. (A‑C) Mass Error Distribution of All Peptides Identified in the Acetylome

    Figure S1. Quality Control Validation of MS Data. (A‑C) Mass Error Distribution of All Peptides Identified in the Acetylome

    Figure S1. Quality control validation of MS data. (A‑C) Mass error distribution of all peptides identified in the acetylome, succi- nylome and quantitative proteome, respectively. (D‑F) Length distribution of peptides identified in the acetylome, succinylome and quantitative proteome, respectively. Figure S2. Comparison of modification level between breast cancer tissue and normal tissue. Comparison of acetylation level (A) and succinylation level (B) between breast cancer tissue and normal tissue. Data are medians and were analyzed using Wilcoxon Signed Rank Test. **P<0.01. Table SI. Protein sites whose acetylation and succinylation levels were both significantly upregulated in breast cancer tissues (fold change ≥1.5 compared with normal tissues). Protein ID Protein name Modification site P54868 HMCS2 310K Q15063 POSTN 549K Q99715 COCA1 1601K P51572 BAP31 72K P07237 PDLA1 328K Q06830 PRDX1 192K P48735 IDHP 180K P30101 PDIA3 417K P0DMV9 HS71B 526K Q01995 TAGL 21K P06748 NPM1 27K Q00325 MPCP 209K P00488 F13A 69K P02545 LMNA 260K P08133 ANXA6 478K P02452 CO1A1 751K Table SII. Protein sites whose acetylation and succinylation levels were both significantly downregulated in breast cancer tissues (fold change ≥1.5 compared with normal tissues). Protein ID Protein name Modification site RET4 P02753 30K PSG2 P07585 142K HBA P69905 12K IGKC P01834 80K HBA P69905 8K Table SIII. All proteins whose expression level were significantly upregulated in breast cancer tissues (fold change ≥1.5 compared with normal tissues). Protein ID Protein description
  • Conserved and Novel Properties of Clathrin-Mediated Endocytosis in Dictyostelium Discoideum" (2012)

    Conserved and Novel Properties of Clathrin-Mediated Endocytosis in Dictyostelium Discoideum" (2012)

    Rockefeller University Digital Commons @ RU Student Theses and Dissertations 2012 Conserved and Novel Properties of Clathrin- Mediated Endocytosis in Dictyostelium Discoideum Laura Macro Follow this and additional works at: http://digitalcommons.rockefeller.edu/ student_theses_and_dissertations Part of the Life Sciences Commons Recommended Citation Macro, Laura, "Conserved and Novel Properties of Clathrin-Mediated Endocytosis in Dictyostelium Discoideum" (2012). Student Theses and Dissertations. Paper 163. This Thesis is brought to you for free and open access by Digital Commons @ RU. It has been accepted for inclusion in Student Theses and Dissertations by an authorized administrator of Digital Commons @ RU. For more information, please contact [email protected]. CONSERVED AND NOVEL PROPERTIES OF CLATHRIN- MEDIATED ENDOCYTOSIS IN DICTYOSTELIUM DISCOIDEUM A Thesis Presented to the Faculty of The Rockefeller University in Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy by Laura Macro June 2012 © Copyright by Laura Macro 2012 CONSERVED AND NOVEL PROPERTIES OF CLATHRIN- MEDIATED ENDOCYTOSIS IN DICTYOSTELIUM DISCOIDEUM Laura Macro, Ph.D. The Rockefeller University 2012 The protein clathrin mediates one of the major pathways of endocytosis from the extracellular milieu and plasma membrane. Clathrin functions with a network of interacting accessory proteins, one of which is the adaptor complex AP-2, to co-ordinate vesicle formation. Disruption of genes involved in clathrin-mediated endocytosis causes embryonic lethality in multicellular animals suggesting that clathrin-mediated endocytosis is a fundamental cellular process. However, loss of clathrin-mediated endocytosis genes in single cell eukaryotes, such as S.cerevisiae (yeast), does not cause lethality, suggesting that clathrin may convey specific advantages for multicellularity.
  • Tepzz¥5Z5 8 a T

    Tepzz¥5Z5 8 a T

    (19) TZZ¥Z___T (11) EP 3 505 181 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 03.07.2019 Bulletin 2019/27 A61K 38/46 (2006.01) C12N 9/16 (2006.01) (21) Application number: 18248241.4 (22) Date of filing: 28.12.2018 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • DICKSON, Patricia GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Torrance, CA California 90502 (US) PL PT RO RS SE SI SK SM TR • CHOU, Tsui-Fen Designated Extension States: Torrance, CA California 90502 (US) BA ME • EKINS, Sean Designated Validation States: Brooklyn, NY New York 11215 (US) KH MA MD TN • KAN, Shih-Hsin Torrance, CA California 90502 (US) (30) Priority: 28.12.2017 US 201762611472 P • LE, Steven 05.04.2018 US 201815946505 Torrance, CA California 90502 (US) • MOEN, Derek R. (71) Applicants: Torrance, CA California 90502 (US) • Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (74) Representative: J A Kemp Torrance, CA 90502 (US) 14 South Square • Phoenix Nest Inc. Gray’s Inn Brooklyn NY 11215 (US) London WC1R 5JJ (GB) (54) PREPARATION OF ENZYME REPLACEMENT THERAPY FOR MUCOPOLYSACCHARIDOSIS IIID (57) The present disclosure relates to compositions for use in a method of treating Sanfilippo syndrome (also known as Sanfilippo disease type D, Sanfilippo D, mu- copolysaccharidosis type IIID, MPS IIID). The method can entail injecting to the spinal fluid of a MPS IIID patient an effective amount of a composition comprising a re- combinant human acetylglucosamine-6-sulfatase (GNS) protein comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and having the en- zymatic activity of the human GNS protein.
  • The Urokinase Receptor: a Multifunctional Receptor in Cancer Cell Biology

    The Urokinase Receptor: a Multifunctional Receptor in Cancer Cell Biology

    International Journal of Molecular Sciences Review The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications Anna Li Santi 1,†, Filomena Napolitano 2,†, Nunzia Montuori 2 and Pia Ragno 1,* 1 Department of Chemistry and Biology, University of Salerno, Fisciano, 84084 Salerno, Italy; [email protected] 2 Department of Translational Medical Sciences, “Federico II” University, 80135 Naples, Italy; fi[email protected] (F.N.); [email protected] (N.M.) * Correspondence: [email protected] † Equal contribution. Abstract: Proteolysis is a key event in several biological processes; proteolysis must be tightly con- trolled because its improper activation leads to dramatic consequences. Deregulation of proteolytic activity characterizes many pathological conditions, including cancer. The plasminogen activation (PA) system plays a key role in cancer; it includes the serine-protease urokinase-type plasminogen activator (uPA). uPA binds to a specific cellular receptor (uPAR), which concentrates proteolytic activity at the cell surface, thus supporting cell migration. However, a large body of evidence clearly showed uPAR involvement in the biology of cancer cell independently of the proteolytic activity of its ligand. In this review we will first describe this multifunctional molecule and then we will discuss how uPAR can sustain most of cancer hallmarks, which represent the biological capabilities acquired during the multistep cancer development. Finally, we will illustrate the main data available in the literature on uPAR as a cancer biomarker and a molecular target in anti-cancer therapy. Citation: Li Santi, A.; Napolitano, F.; Montuori, N.; Ragno, P. The Keywords: urokinase receptor; uPAR; cancer hallmarks Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology.
  • Folate Receptor Β Regulates Integrin Cd11b/CD18 Adhesion of a Macrophage Subset to Collagen

    Folate Receptor Β Regulates Integrin Cd11b/CD18 Adhesion of a Macrophage Subset to Collagen

    Folate Receptor β Regulates Integrin CD11b/CD18 Adhesion of a Macrophage Subset to Collagen This information is current as Christian Machacek, Verena Supper, Vladimir Leksa, Goran of September 24, 2021. Mitulovic, Andreas Spittler, Karel Drbal, Miloslav Suchanek, Anna Ohradanova-Repic and Hannes Stockinger J Immunol 2016; 197:2229-2238; Prepublished online 17 August 2016; doi: 10.4049/jimmunol.1501878 Downloaded from http://www.jimmunol.org/content/197/6/2229 Supplementary http://www.jimmunol.org/content/suppl/2016/08/17/jimmunol.150187 Material 8.DCSupplemental http://www.jimmunol.org/ References This article cites 49 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/197/6/2229.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 24, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Folate Receptor b Regulates Integrin CD11b/CD18 Adhesion of a Macrophage Subset to Collagen Christian Machacek,* Verena Supper,* Vladimir Leksa,*,† Goran Mitulovic,‡ Andreas Spittler,x Karel Drbal,{,1 Miloslav Suchanek,{ Anna Ohradanova-Repic,* and Hannes Stockinger* Folate, also known as vitamin B9, is necessary for essential cellular functions such as DNA synthesis, repair, and methylation.
  • Aldolase C (C-Terminus Specific) Data Sheet

    Aldolase C (C-Terminus Specific) Data Sheet

    Aldolase C (C-terminus Specific) Data Sheet Catalog Number: MO22157 Host: Mouse Product Type: Monoclonal IgG1 Species Human, horse, cow, pig, Affinity Purified Antibody Reactivity: chicken, rat, mouse Immunogen Sequence: C-terminal sequence Format: Liquid, 100 ul aliquot KYEGSGEDGGAAAQSLYIANHAY Concentration: 1 mg/ml HGNC name for this protein is ALDOC Applications: Immunofluorescence/Immunocytochemistry: 1:500-1:1,000 Immunohistochemistry: 1: 500-1:1,000 Western Blot: 1:1,000 Dilutions listed as a recommendation. Optimal dilution should be determined by investigator. Storage: Antibody can also be aliquoted and stored frozen at -20° C to -70° C in a manual defrost freezer for six months without detectable loss of activity. The antibody can be stored at 2° - 8° C for 1 month without detectable loss of activity. Avoid repeated freeze-thaw cycles. Application Notes Description/Data: Aldolase A is generally considered to be a muscle enzyme. Northern analysis of cultured cells suggests that it is present in both neurons and glia. Aldolase C shares 81% amino acid identity with aldolase A and 70% identity with aldolase B. Earlier studies using isozyme-specific antibodies report its location in gray matter astrocytes and cells of the pia mater. In situ hybridization of mouse central nervous system using isozyme-specific probes revealed that aldolase A and C are expressed in complementary cell types: aldolase A mRNA is found in neurons; aldolase C message is detected in astrocytes, some cells of the pia mater, and Purkinje cells. Aldolase C can in some situations be used as an astrocyte marker. However Purkinje cells of the cerebellum contain high levels of the enzyme, so the enzyme is not totally astrocyte specific.
  • Datasheet: VPA00226

    Datasheet: VPA00226

    Datasheet: VPA00226 Description: RABBIT ANTI ALDOA Specificity: ALDOA Format: Purified Product Type: PrecisionAb™ Polyclonal Isotype: Polyclonal IgG Quantity: 100 µl Product Details Applications This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols. Yes No Not Determined Suggested Dilution Western Blotting 1/1000 PrecisionAb antibodies have been extensively validated for the western blot application. The antibody has been validated at the suggested dilution. Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Further optimization may be required dependant on sample type. Target Species Human Species Cross Reacts with: Mouse, Rat Reactivity N.B. Antibody reactivity and working conditions may vary between species. Product Form Purified IgG - liquid Preparation Rabbit Ig fraction prepared by ammonium sulphate precipitation Buffer Solution Phosphate buffered saline Preservative 0.09% Sodium Azide (NaN3) Stabilisers Immunogen KLH conjugated synthetic peptide between 66-95 amino acids from the N-terminal region of human ALDOA External Database UniProt: Links P04075 Related reagents Entrez Gene: 226 ALDOA Related reagents Page 1 of 2 Synonyms ALDA Specificity Rabbit anti Human ALDOA antibody recognizes fructose-bisphosphate aldolase A, also known as epididymis secretory sperm binding protein Li 87p, fructose-1,6-bisphosphate triosephosphate-lyase, lung cancer antigen NY-LU-1 and muscle-type aldolase. Encoded by the ALDOA gene, fructose-bisphosphate aldolase A is a glycolytic enzyme that catalyzes the reversible conversion of fructose-1,6-bisphosphate to glyceraldehyde 3-phosphate and dihydroxyacetone phosphate.